Upside case
Bull case
$647+110.2%
SYK would need investors to value it at roughly 43x earnings — about 23x more generous than today's 21x forward P/E. That requires meaningful multiple expansion on top of continued earnings growth.
Analysis OverviewBuyUpdated Jun 18, 2026
Stryker Corporation (SYK) Stock Analysis
Wall Street verdict, consensus price target, and analyst rating breakdown — everything needed to frame the risk/reward at today's price.
Analyst consensus
Buy
Covering
51
analysts
37 bullish · 0 bearish · 51 covering SYK
Strong Buy
1
Buy
36
Hold
14
Sell
0
Strong Sell
0
Consensus Target
$387
+25.9% vs today
Scenario Range
$309 – $647
Model bear to bull value window
Coverage
51
Published analyst ratings
Valuation Context
20.5x
Forward P/E · Market cap $117.9B
SYK price targets
Three scenarios for where SYK stock could go
Current
~$308
Confidence
55 / 100
Updated
Jun 18, 2026
Where we are now
Current · $308
Bear
$309
Base
$491
Bull
$647
Market caseClosest to today
Base case
$491+59.5%
At 33x on FY1 earnings, the base case reflects a reasonable but not stretched valuation. It prices in continued growth without assuming an exceptional setup.
Stress case
Bear case
$309+0.5%
The bear case assumes sentiment or fundamentals disappoint enough to push SYK down roughly 0% from the current price.
Not financial advice. Model confidence reflects internal scenario assumptions, not a guarantee of returns. Past performance does not predict future results.
Stryker Corporation
SYK · NYSEHealthcareMedical - DevicesDecember year-end
Stryker is a medical technology company that develops and sells surgical equipment, orthopedic implants, and neurotechnology devices. It generates revenue primarily through two segments: MedSurg and Neurotechnology (roughly 55% of sales) and Orthopaedics and Spine (roughly 45%), selling everything from joint replacement implants to surgical navigation systems. The company's competitive advantage lies in its broad product portfolio across multiple surgical specialties and its strong relationships with hospitals—creating switching costs through integrated systems and surgeon training.
Market Cap
$117.9B
Revenue TTM
$25.1B
Net Income TTM
$3.2B
Net Margin
12.9%
SYK Revenue and Earnings Performance
Quarterly beat-or-miss track record against analyst estimates, plus forward revenue and EPS outlook for the next two fiscal years.
EPS Beat Rate
92%Exceptional
12 quarters tracked
Revenue Beat Rate
92%Exceptional
vs consensus estimates
Avg EPS Surprise
+2.1%
above Street consensus
Beat / Miss Record
BeatMissLeft = EPS · Right = Revenue
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Last 4 Quarters
EPS beats: 3 of 4Q3 2025
EPS
$3.13/$3.07
Revenue
$6.0B/$5.9B
Q4 2025
EPS
$3.19/$3.13
Revenue
$6.1B/$6.0B
Q1 2026
EPS
$4.47/$4.40
Revenue
$7.2B/$7.1B
Q2 2026
EPS
$2.60/$2.98
Revenue
$6.0B/$6.3B
| Quarter | EPS (Actual / Est) | EPS Surprise | Revenue (Actual / Est) | Rev Surprise |
|---|---|---|---|---|
| Q3 2025 | $3.13/$3.07 | +2.0% | $6.0B/$5.9B | +1.4% |
| Q4 2025 | $3.19/$3.13 | +1.9% | $6.1B/$6.0B | +0.2% |
| Q1 2026 | $4.47/$4.40 | +1.6% | $7.2B/$7.1B | +0.7% |
| Q2 2026 | $2.60/$2.98 | -12.8% | $6.0B/$6.3B | -5.0% |
FY1–FY2 Estimates
Revenue Outlook
FY1
$27.7B
+10.1% YoY
FY2
$30.0B
+8.5% YoY
EPS Outlook
FY1
$12.12
+44.4% YoY
FY2
$13.21
+9.0% YoY
Trailing FCF (TTM)$4.3B
FCF Margin: 17.1%
Next Earnings
July 30, 2026
Expected EPS
$3.49
Expected Revenue
$6.6B
SYK beat EPS estimates in 3 of 4 tracked quarters. A strong delivery record supports forward estimate credibility.
SYK Revenue Breakdown by Segment
Product and geographic revenue mix from the latest annual disclosure, with year-over-year growth by segment.
Latest disclosure
FY 2025
Total disclosed revenue $25.1B
Product Mix
Latest annual revenue by segment or product family
MedSurg
62.3%
+15.7% YoY
Tap, hover, or focus a slice to inspect segment detail.
Geographic Mix
Latest annual revenue by reported region
EMEA
52.1%
+9.8% YoY
Tap, hover, or focus a slice to inspect segment detail.
MedSurg is the largest disclosed segment at 62.3% of FY 2025 revenue, up 15.7% YoY.
EMEA is the largest reported region at 52.1%, up 9.8% YoY.
SYK Valuation Snapshot
Current multiples compared to the S&P 500, the company's sector, and its own five-year average.
Relative Value Signal
Expensive versus peers
Fair value est. $214 — implies -30.3% from today's price.
Premium to Fair Value
30.3%
above fair value
Deep DiscountFair ValueVery Expensive
vs S&P 500 Trailing P/E
SYK
36.6x
vs
S&P 500
24.4x
+50% premium
vs Healthcare Trailing P/E
SYK
36.6x
vs
Healthcare
22.1x
+66% premium
vs SYK 5Y Avg P/E
Today
36.6x
vs
5Y Average
43.1x
15% discount
Forward PE
20.5x
S&P 500
18.8x
+9%
Healthcare
18.3x
+12%
5Y Avg
—
—
Trailing PE
36.6x
S&P 500
24.4x
+50%
Healthcare
22.1x
+66%
5Y Avg
43.1x
-15%
PEG Ratio
2.46x
S&P 500
1.66x
+48%
Healthcare
1.59x
+55%
5Y Avg
—
—
EV/EBITDA
21.2x
S&P 500
15.2x
+39%
Healthcare
14.2x
+49%
5Y Avg
23.5x
-10%
Price/FCF
27.5x
S&P 500
20.7x
+33%
Healthcare
18.5x
+48%
5Y Avg
38.2x
-28%
Price/Sales
4.7x
S&P 500
3.1x
+52%
Healthcare
2.6x
+78%
5Y Avg
5.6x
-17%
Dividend Yield
1.09%
S&P 500
1.91%
-43%
Healthcare
1.50%
-27%
5Y Avg
0.98%
+12%
| Metric | SYK | S&P 500 | Healthcare | 5Y Avg SYK |
|---|---|---|---|---|
| Forward PE | 20.5x | 18.8x | 18.3x+12% | — |
| Trailing PE | 36.6x | 24.4x+50% | 22.1x+66% | 43.1x-15% |
| PEG Ratio | 2.46x | 1.66x+48% | 1.59x+55% | — |
| EV/EBITDA | 21.2x | 15.2x+39% | 14.2x+49% | 23.5x-10% |
| Price/FCF | 27.5x | 20.7x+33% | 18.5x+48% | 38.2x-28% |
| Price/Sales | 4.7x | 3.1x+52% | 2.6x+78% | 5.6x-17% |
| Dividend Yield | 1.09% | 1.91% | 1.50% | 0.98% |
SYK trades above S&P 500 benchmarks on 5 of 6 measured multiples — commands a broad premium across most valuation dimensions.
Forward P/E and PEG reflect analyst consensus estimates. Historical averages use trailing ratios where forward data is unavailable.S&P 500 and sector benchmarks both use trailing median P/E — similar readings indicate the broader index and sector are priced alike.
Open valuation toolSYK Financial Health
Verdict
Strong
SYK generates $4.3B in free cash flow at a 17.1% margin — 11.4% ROIC signals a durable competitive advantage · returns 1.1% of market cap to shareholders annually.
Cash Engine
Revenue, margins, and cash generation
Revenue (TTM)
Trailing-twelve-month sales base
$25.1B
Revenue Growth
TTM vs prior year
+11.2%
Gross Margin
Gross profit as a share of revenue
63.5%
Operating Margin
Operating income divided by revenue
22.4%
Net Margin
Net income divided by revenue
12.9%
EPS (TTM)
Diluted earnings per share, trailing twelve months
$8.40
Free Cash Flow (TTM)
Cash generation after capex
$4.3B
FCF Margin
FCF as share of revenue — the primary cash quality signal
17.1%
Capital Quality
ROIC, leverage, and debt serviceability
ROIC
Return on invested capital — primary competitive quality signal
11.4%
ROA
Return on assets, trailing twelve months
6.9%
Cash & Equivalents
Liquid assets on the balance sheet
$4.0B
Net Debt
Total debt minus cash
$10.8B
Debt Serviceability
Net debt as a multiple of annual free cash flow
2.5× FCF
~2.5 years to full repayment at current FCF run-rate
ROE
Return on equity, trailing twelve months
15.0%
Shareholder Returns
How capital is returned to owners
Total shareholder yield
1.1%
Dividend
1.1%
Buyback
0.0%
Share Repurchases
Trailing buyback outflow — dollar magnitude of capital returned
$0
Dividend / Share
Annualized trailing dividend per share
$3.36
Payout Ratio
Share of earnings distributed as dividends
39.6%
Shares Outstanding
Current diluted share count
383M
All figures from the trailing twelve months. ROIC uses invested capital (equity + net debt).
Open full ratios pageSYK Stock Risk Factors
Key factors that could pressure the stock price, compress the multiple, or weigh on future results.
AI analysis · updated June 17, 2026
Medium
Stock Price Decline
The SYK stock closed at 309.90 on June 15, 2026, reflecting a decline of 0.70% from the previous close of 312.10.
Medium
Bearish Technical Trend
Short-term technicals show a bearish trend with an RSI of 22, suggesting potential further downside.
Lower
Revenue Growth Slowdown
Revenue growth is reported at +2.6%, which may indicate slower expansion compared to historical performance.
Medium
Valuation Concerns
The P/E ratio of 35.0 may raise valuation concerns if growth does not accelerate.
High Risk
Market Sentiment Shift
Analyst ratings suggest a HOLD with weak signal strength (3/7), indicating cautious or negative market sentiment.
These are risk mechanisms, not predictions. The key question is which would force a cut to earnings estimates or a lower multiple than the market currently prices in.
Why SYK Stock Could Outperform
Structural drivers behind the upside case and why the stock could outperform over the next 12 months.
AI analysis · updated June 17, 2026
Wide economic moat
Stryker Corporation has a wide moat, indicating strong competitive advantages and sustainable profitability in the medical devices sector.
Steady procedure demand
The company benefits from consistent demand for medical procedures, supporting stable revenue growth.
Innovation in devices and robotics
Stryker's continued advancements in medical devices and robotics position it as a leader in healthcare technology.
Strong institutional ownership
Top holders like The Vanguard Group (8.8%) demonstrate significant institutional confidence in Stryker's long-term prospects.
Solid financial performance
Recent Q1 2026 sales of US$6,020 million, higher net income, and a maintained US$0.88 dividend reflect robust financial health.
Management execution
Stryker's leadership has shown ability to protect margins despite regulatory, supply chain, and pricing pressures.
Healthcare sector resilience
Operating in the healthcare-medical devices sector provides Stryker with defensive characteristics against economic downturns.
A real bull case compounds — each driver matters most when it strengthens margins, supports capital returns, and keeps the company above the market's minimum growth bar simultaneously.
SYK Stock Price Performance
52-week range context and price returns across multiple time horizons. Dividend contribution is shown separately in the Capital Return section.
Current Price
$307.80
52W Range Position
22%
52-Week Range
Current price plotted between the 52-week low and high.
52-Week Low
$281.00
+9.5% from the low
52-Week High
$404.87
-24.0% from the high
1 Month
-1.73%
3 Month
-10.99%
YTD
-11.6%
1 Year
-17.5%
3Y CAGR
+1.1%
5Y CAGR
+3.8%
10Y CAGR
+10.2%
Range context matters because valuation compression and earnings misses rarely hit from the same starting point. A stock already far below its high can still fall, but it is no longer carrying the same embedded optimism as one pressing a fresh peak.
SYK vs Peers
Valuation, growth, and margin comparison against the closest publicly traded peers for this company.
Peer Set
Accurate peer set
Forward PE
20.5x
vs 13.3x median
+54% above peer median
Revenue Growth
+10.1%
vs +7.9% median
+28% above peer median
Net Margin
12.9%
vs 13.0% median
-1% below peer median
| Company | Mkt Cap | Fwd PE | Rev Grw | Margin | Rating | Upside |
|---|---|---|---|---|---|---|
SYK SYK Stryker Corporation | $117.9B | 20.5x | +10.1% | 12.9% | Buy | +25.9% |
ZBH ZBH Zimmer Biomet Holdings, Inc. | $17.2B | 10.4x | +4.2% | 9.1% | Hold | +9.5% |
BSX BSX Boston Scientific Corporation | $67.3B | 13.5x | +9.7% | 14.4% | Buy | +83.0% |
EW EW Edwards Lifesciences Corporation | $50.4B | 29.0x | +9.8% | 17.6% | Buy | +10.5% |
BDX BDX Becton, Dickinson and Company | $52.2B | 11.4x | +5.4% | 5.3% | Hold | +21.4% |
MDT MDT Medtronic plc | $101.9B | 13.3x | +7.9% | 13.0% | Buy | +20.7% |
This peer comparison reflects companies with similar business models, product lines, or market positioning, supplemented by industry grouping when direct matches are limited.
SYK Dividend and Capital Return
SYK returns 1.1% total yield, led by a 1.09% dividend, raised 16 consecutive years.
Dividend SustainableFCF Well Covered
Total Shareholder Yield
1.1%
Dividend + buyback return per year
Buyback Yield
0.0%
Dividend Yield
1.09%
Payout Ratio
39.6%
How SYK Splits Its Return
Div 1.09%
Dividend 1.09%Buybacks 0.0%
Dividend Profile
Yield, cadence, and growth quality
Dividend / Share
Trailing annualized cash dividend
$3.36
Growth Streak
Consecutive years of dividend increases
16Y
3Y Div CAGR
6.2%
5Y Div CAGR
7.6%
Ex-Dividend Date
—
Payment Cadence
Semi-Annual
5 payments over the last 12 months
Buyback Engine
How much per-share support comes from repurchases
Repurchases (TTM)
Cash used for buybacks in the latest trailing period
$0
Estimated Shares Retired
0
Approx. Share Reduction
0.0%
Shares Outstanding
Current diluted share count from the screening snapshot
383M
| Year | Div / Share | YoY Grw | BB Yield | Total Yield |
|---|---|---|---|---|
| 2026 | $1.76 | — | — | — |
| 2025 | $3.40 | +4.9% | 0.0% | 1.0% |
| 2024 | $3.24 | +6.2% | 0.1% | 1.0% |
| 2023 | $3.05 | +7.6% | 0.1% | 1.1% |
| 2022 | $2.83 | +9.7% | 0.1% | 1.3% |
FAQ
7 questionsSYK Investor Questions
Common questions answered from live analyst data and company financials.
01Is Stryker Corporation (SYK) stock a buy or sell in 2026?
Stryker Corporation (SYK) is rated Buy by Wall Street analysts as of 2026. Of 51 analysts covering the stock, 37 rate it Buy or Strong Buy, 14 rate it Hold, and 0 rate it Sell or Strong Sell. The consensus 12-month price target is $387, implying +25.9% from the current price of $308. The bear case scenario is $309 and the bull case is $647.
02What is the SYK stock price target for 2026?
The Wall Street consensus price target for SYK is $387 based on 51 analyst estimates. The high-end target is $465 (+51.1% from today), and the low-end target is $315 (+2.3%). The base case model target is $491.
03Is Stryker Corporation (SYK) stock overvalued in 2026?
SYK trades at 20.5x times forward earnings. The stock trades at a notable premium to the broad market, which is typical for businesses with strong free cash flow and above-average growth expectations. Based on current multiples versus the peer group, the relative model signals expensive versus peers. Whether the stock is over or undervalued ultimately depends on whether consensus earnings estimates are achievable.
04What are the main risks for Stryker Corporation (SYK) stock in 2026?
The primary risks for SYK in 2026 are: (1) Market Sentiment Shift — Analyst ratings suggest a HOLD with weak signal strength (3/7), indicating cautious or negative market sentiment. (2) Stock Price Decline — The SYK stock closed at 309. (3) Bearish Technical Trend — Short-term technicals show a bearish trend with an RSI of 22, suggesting potential further downside. Each factor has the potential to pressure earnings or compress the stock's valuation multiple.
05What is Stryker Corporation's revenue and earnings forecast?
Analyst consensus estimates SYK will report consensus revenue of $27.7B (+10.1% year-over-year) and EPS of $12.12 (+44.4% year-over-year) for the upcoming fiscal year. The following year, analysts project $30.0B in revenue.
06When does Stryker Corporation (SYK) report its next earnings?
Stryker Corporation is expected to report its next earnings on approximately 2026-07-30. Consensus expects EPS of $3.49 and revenue of $6.6B. Over recent quarters, SYK has beaten EPS estimates 92% of the time.
07How much free cash flow does Stryker Corporation generate?
Stryker Corporation (SYK) generated $4.3B in free cash flow over the trailing twelve months — a free cash flow margin of 17.1%. SYK returns capital to shareholders through dividends (1.1% yield) and share repurchases ($0 TTM).